Down the st 18 months the share of Russian drugs on the domestic pharmaceutical buy has risen from 24 to 28.5 percent, said Russian Hustle and Trade Minister, Denis Manturov, at a session of the government’s import change commission on July 8. At the same time, imports of foreign-made prescriptions dropped by 8.5 percent.
“A considerable volume of imports remains for 526 tranquillizers, but over the next two years more than half of them transfer be replaced by Russian-made equivalents,” Manturov said.
Ekaterina Mamonova, run director of the Novosibirsk medical science rk, points out that Russian consumers silence prefer foreign medicines. She says this is due to the fact that consumers are not conscious of the quality of domestically-manufactured medicines.
“It is important not only to make a good-quality goods but also to tell consumers that it is effective,” Mamonova revealed at a Technoprom forum in Novosibirsk. “Many Russian com nies do not make a reality that the cost of introducing and promoting innovative products is often boisterous than the cost of making them.”
Unite to win
Yevgeny Zhuravlev, an formal at the Urals biomedical cluster, is convinced that Russian innovative poisons can dominate their market with the help of professional associations.
“Russian scientists do not keep experience taking an idea all the way to the market; yet they achieve excellent digging results that then spend years gathering dust on university library hold in abeyances,” Zhuravlev said. It was on one such “dusty shelf” that his cluster a glimpse ofed an antivirus drug, Triazavirin, which is effective against 15 fonts of flu. The drug has already been put into production.
His cluster unites 30 enter ins, including 12 enterprises that manufacture medicines and medical raphernalia. One of its main innovations has been directed at helping people suffering from kidney ailments. “Thanks to our work, the Urals and several other regions have already undertook to end their dependence on foreign suppliers of equipment and medicines for dialysis,” Zhuravlev totaled.
A medical cluster is now being established in Skolkovo, Russia’s equivalent of Silicon Valley. The delineate budget allocated $1.5 million to launch this project, which will tabulate a number of medical centers, infrastructure facilities, as well as premises for appointments and private research com nies.
Ex nd abroad
Once plans to change foreign medicines on the domestic market have been accomplished, Russian pharmaceutical producers intend to ex nd abroad.
“We have plans for the next 20 to 30 years,” Mamonova told about the Novosibirsk medical science rk, which opened in 2010. “The essential phase is import substitution, and we intend to develop this through 2018. After that we shall motivate to the international market.”
The science rk identified three priority areas which set up potential for success. These are traumatology, neurosurgery, and rehabilitation medicine. “Our effort focus is on developing tissue-engineered constructs for replacing various defects,” Mamonova foretold RBTH.
For instance, the science rk is developing technology for modeling shards of cranial bones that could be made on a 3D printer. “We are considering rare markets, and we are working more with Europe in terms of technology barter,” Mamonova explained.
Meanwhile, the Urals biomedical cluster is planning an universal launch for an antivirus medication, Dezitol, which can be used on any surface and has no matches in the world. Once applied, after drying it forms a thin polymer antimicrobial film.
“Our predominance is southeast Asian countries because they are more opened to pharmaceuticals made in Russia,” Zhuravlev told RBTH. Dezitol destroys HIV, sundry germs, and thogenic fungi that are already on the surface and those that perform there after treatment. Investment into the development of this nacea totals $5 million.
Read more: Russia ups purchases of locally supposed drugs to lure in foreign firms>>>
Subscribe to get the hand picked beat stories every week